Home-Based Stimulation for Bipolar Depression Shows Mixed Efficacy

Bipolar disorder is characterised by recurrent episodes of mania and depression, with depressive phases often proving more debilitating and challenging to treat. Current treatment guidelines recommend a combination of mood stabilisers, atypical antipsychotics, and psychotherapy. Despite these options, a significant proportion of patients experience residual symptoms or inadequate response, prompting interest in adjunctive therapies. Neuromodulation techniques, such as transcranial direct current stimulation (tDCS), have emerged as potential non-invasive interventions. tDCS involves delivering a low-amplitude electrical current to specific brain regions, aiming to modulate neuronal excitability. The appeal of home-based tDCS lies in its potential to increase accessibility and adherence, reducing the burden of clinic visits for patients with chronic conditions like bipolar depression. However, the transition from supervised clinical settings to unsupervised home use introduces variables that can affect treatment fidelity and outcomes.

What the studies did

Several trials have investigated the efficacy and safety of home-based tDCS for bipolar depression. These studies typically involve patients self-administering tDCS using portable devices, often guided by remote supervision or pre-programmed protocols. A common design involves daily sessions over several weeks, with active tDCS compared to a sham condition where the device delivers only a brief initial current burst to mimic the sensation of active stimulation without therapeutic effect. Primary outcome measures generally include changes in validated depression rating scales, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HDRS). Secondary outcomes often assess mood stability, quality of life, and adverse events. Patient populations typically include individuals diagnosed with bipolar I or II disorder, currently experiencing a depressive episode, and often on stable psychotropic medication regimens. Inclusion criteria frequently specify a minimum baseline depression score to ensure a clinically relevant level of depressive symptoms.^1,2

One randomised, sham-controlled trial enrolled 120 patients with bipolar depression. Participants received 20 minutes of 2 mA tDCS daily for 6 weeks, targeting the left dorsolateral prefrontal cortex (DLPFC) with the anode and the right supraorbital region with the cathode. The study reported a mean reduction in MADRS scores of -10.2 points in the active tDCS group compared to -7.7 points in the sham group, resulting in a difference of 2.5 points (p=0.048).¹ However, this difference, while statistically significant, was at the lower end of what is considered clinically meaningful for MADRS (typically 2-4 points). Another trial, involving 80 patients, found no statistically significant difference in HDRS scores between active tDCS and sham at the primary endpoint (p=0.12).² Response rates, defined as a ≥50% reduction in baseline depression scores, also varied, with one study reporting a response rate of 35% in the active group versus 20% in the sham group (p=0.06), narrowly missing statistical significance.³ Remission rates, defined as a MADRS score of ≤10, were similarly inconsistent across trials.^1,2,3

Adverse events reported in these studies were generally mild and transient, primarily consisting of scalp itching, tingling, or discomfort at the electrode sites. No serious adverse events directly attributable to tDCS were consistently reported across trials. This safety profile is consistent with previous research on tDCS in other psychiatric conditions. However, adherence to the home-based protocol varied, with some studies reporting completion rates as low as 60%, which could influence overall efficacy data. The lack of direct supervision also raises questions about the consistency of electrode placement and device operation by patients, potentially introducing variability in the delivered current and therapeutic effect.^1,2,3

The mixed results highlight several limitations. Sample sizes in many home-based tDCS trials for bipolar depression have been relatively small, potentially limiting the power to detect modest but clinically relevant effects. Heterogeneity in study designs, including differences in stimulation parameters (current intensity, duration, frequency), electrode placement, and patient populations (e.g., specific bipolar subtypes, concomitant medications), makes direct comparisons challenging. The placebo effect in neuromodulation studies is also substantial, and the ability of sham conditions to truly blind participants can be imperfect, especially with repeated home use. Future research needs to address these methodological challenges, potentially through larger, multi-centre trials with standardised protocols and objective measures of adherence and stimulation delivery. Investigating specific patient subgroups who might benefit most from tDCS, perhaps based on neuroimaging biomarkers or clinical profiles, could also refine its application.⁴